)
)
Kyverna Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Kyverna Therapeutics Inc
Access all reports
Kyverna Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for autoimmune diseases. The company focuses on chimeric antigen receptor (CAR) T-cell therapies, which are designed to reset the immune system and potentially offer sustained treatment-free remission for patients. Kyverna’s main product candidate, KYV-101, is an autologous CD19 CAR T-cell therapy currently in clinical trials for various autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and multiple sclerosis. Additionally, Kyverna is developing KYV-201, an allogeneic CAR T-cell therapy, and exploring treatments for other autoimmune diseases including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The company is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.
Latest articles
)
James Quincey: Coca-Cola Chairman and CEO
James Quincey has dedicated nearly three decades to The Coca-Cola Company, rising through the ranks to become CEO and Chairman of the company.
11 Mar 2025
)
PepsiCo: From Pepsi and Gatorade to Doritos and Lay's
PepsiCo has grown from a soda company into a global leader in food and beverages, with a portfolio of over 200 brands, including Pepsi, Lay's, and Gatorade.
11 Mar 2025
)
Bob Iger: Disney's Visionary CEO
Bob Iger is a legend in the entertainment industry, known for his visionary leadership and as one of the most influential CEOs in Disney's history.
10 Mar 2025
Ticker symbol
KYTX
Country
🇺🇸 United States